US 12,004,868 B2
Liposomal mitigation of drug-induced inhibition of the cardiac IKr channel
Lawrence Helson, Quakertown, PA (US); George M. Shopp, Boulder, CO (US); and Annie Bouchard, Stoke (CA)
Assigned to Signpath Pharma Inc., Sandy, UT (US)
Filed by Signpath Pharma, Inc., Sandy, UT (US)
Filed on Jun. 5, 2019, as Appl. No. 16/432,498.
Application 16/432,498 is a continuation of application No. 15/403,831, filed on Jan. 11, 2017, granted, now 10,349,884.
Application 15/403,831 is a continuation in part of application No. 15/347,381, filed on Nov. 9, 2016, granted, now 10,117,881, issued on Nov. 6, 2018.
Application 15/347,381 is a continuation in part of application No. 15/068,300, filed on Mar. 11, 2016, granted, now 10,617,639.
Application 15/403,831 is a continuation in part of application No. 14/575,644, filed on Dec. 18, 2014, granted, now 10,532,045.
Application 15/068,300 is a continuation of application No. 14/268,376, filed on May 2, 2014, granted, now 9,682,041, issued on Jun. 20, 2017.
Application 14/268,376 is a continuation of application No. 13/487,233, filed on Jun. 3, 2012, granted, now 8,753,674, issued on Jun. 17, 2014.
Claims priority of provisional application 61/977,417, filed on Apr. 9, 2014.
Claims priority of provisional application 61/917,426, filed on Dec. 18, 2013.
Claims priority of provisional application 61/493,257, filed on Jun. 3, 2011.
Prior Publication US 2019/0320975 A1, Oct. 24, 2019
This patent is subject to a terminal disclaimer.
Int. Cl. A61B 5/00 (2006.01); A61B 5/364 (2021.01); A61K 9/00 (2006.01); A61K 9/127 (2006.01); A61K 31/12 (2006.01); A61K 31/445 (2006.01); A61K 31/4545 (2006.01); A61K 31/506 (2006.01); A61K 31/683 (2006.01)
CPC A61B 5/4848 (2013.01) [A61B 5/364 (2021.01); A61K 9/0019 (2013.01); A61K 9/127 (2013.01); A61K 31/12 (2013.01); A61K 31/445 (2013.01); A61K 31/4545 (2013.01); A61K 31/506 (2013.01); A61K 31/683 (2013.01); A61B 2503/42 (2013.01)] 10 Claims
OG exemplary drawing
 
1. A composition for treating one or more cardiac channelopathies or conditions resulting from irregularities or alterations in cardiac patterns, or both, in a human or animal subject consisting of:
one or more pharmacologically active agents that causes at least one of IKr channel inhibition or QT prolongation by inhibiting the activity of an ether-a-go-go-related gene, wherein the one or more active agents is selected from at least one of: aloxi; amiodarone; arsenic trioxide; astemizole; bepridil; chloroquine; chlorpheniramine; chlorpromazine; cisapride; celaxa; citalopram; clarithromycin; crizotinib; curcumin; disopyramide; dofetilide; domperidone; dronedarone; droperidol; erythromycin; gripafloxacin; haldol; haloperidol; halofantrine; ibutilide; levomethadyl; lidoflazine; loratidine; lovostatin; mesoridazone; methadone; methanesulphonanilide; moxifloxacin; nilotinib; palonasitron; pentamadine; pimozide; prenylamine; probucol; procainamide; propafenone; pyrilamine; quinidine; terfenidine; thorazine; sertindole; sotalol; sparfloxacin; terodiline; thioridazine; and vandetanib; and
empty liposomes of DMPC (1,2-dimyristoyl-sn-glycero-3-phosphocholine), DMPG (1,2-dimyristoyl-sn-glycero-3-phospho-rac-[1-glycerol]), or both administered prior to, concomitantly, or after administration of the one or more pharmacologically active agent, wherein the DMPC is provided in an amount effective to reduce the cardiac channelopathies or conditions resulting from irregularities or alterations in cardiac patterns; and
one or more pharmaceutically acceptable dispersion mediums, solvents, or vehicles.